NCT00619489View on ClinicalTrials.gov

Long Term Safety of Vedolizumab (MLN0002) in Patients With Ulcerative Colitis and Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Ulcerative ColitisCrohn's Disease
Interventions
DRUG

vedolizumab

Vedolizumab for intravenous (IV) infusion

Trial Locations (1)

Unknown

London Health Sciences Centre, London

Sponsors
All Listed Sponsors
lead

Millennium Pharmaceuticals, Inc.

INDUSTRY